PVLA
Palvella Therapeutics Inc.
$120.03
$0.00(0.00%)
45
Overall
--
Value
45
Tech
--
Quality
Market Cap
$937.64M
Volume
187.75K
52W Range
$18.23 - $151.18
Target Price
$229.44
Company Overview
| Mkt Cap | $937.64M | Price | $120.03 |
| Volume | 187.75K | Change | +0.00% |
| P/E Ratio | -53.8 | Open | $117.85 |
| Revenue | -- | Prev Close | $120.03 |
| Net Income | $-17.4M | 52W Range | $18.23 - $151.18 |
| Div Yield | N/A | Target | $229.44 |
| Overall | 45 | Value | -- |
| Quality | -- | Technical | 45 |
No chart data available
About Palvella Therapeutics Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Latest News
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), MAIA Biotechnology, Inc. (MAIA) and Palvella Therapeutics (PVLA)
Howard Kim•7 days ago
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI) and Palvella Therapeutics (PVLA)
Catie Powers•20 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PVLA | $120.03 | 0% | 187.75K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Palvella Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW